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Patients who failed a catheter-free trial after acute urinary retention and one week of full dose alpha-blocker and 5-alpha-reductase
inhibitor were offered Diethylstilbestrol 1mg plus Aspirin 100mg over 4 weeks. Prostate volume, age, serum creatinine, and initial
retention drained urine volume were recorded. After excluding cardiovascular morbidity (𝑛 = 7), upper urinary tract dilation
(𝑛 = 3), compromised renal function (𝑛 = 2), urinary tract infection (𝑛 = 2), neurological diagnosis (𝑛 = 2), or preferred immediate
channel transurethral resection of prostate (𝑛 = 5), 48 of 69 consecutive patients ≥70 years were included. Mean age was 76.6 years
(70–84), mean prostate volume 90 cm3 (42–128), and mean follow-up 204 days; 58% (28/48) were passing urine and 42% (20/48)
were catheter dependent after 4 weeks Diethylstilbestrol trial. Mean age and drained urine volume of catheter dependent patients
were 82.4 years and 850mL compared with 74.6 years and 530mL in catheter-free men, respectively. Age and drained urine volume
were independent predictors of catheter-free trial (both 𝑃 < 0.01). Seventy-five percent (6/8) of patients 80 years and older were
catheter dependent. Transient nipple/breast tenderness and gynecomastia were the only adverse effects reported by 21% (10/48)
and 4% (2/48), respectively. No patient presented severe complications.
1. Introduction
Acute urinary retention (AUR) is an important urological
emergency in men [1–3]. It is characterized by a sudden and
painful inability to pass urine voluntarily [1, 4]. Approxi-
mately 10% of men aged 70 and a third of men aged 80 will
have an AUR in the next 5 years [5].
Management of AUR consists of immediate bladder
decompression by catheterization. The method and duration
of catheterization as an initial treatment are primarily depen-
dent within and among the countries, as is the decision to
admit or send home after catheterization [1, 6, 7]. Usually,
standard management of nonhigh pressure acute retention is
alpha-blocker for at least 48 hours followed by trial without
catheter (TWOC) [6, 8, 9].
Subsequent handling is not well filed due to lack of guide-
lines, mainly in those who fail TWOC [1]. This study aims to
evaluate efficacy, safety, and adverse effects of DES 1mg plus
aspirin 100mg over 4 weeks as a minimally invasive alterna-
tive in an elderly population presenting with AUR secondary
to prostatic obstruction who failed a catheter-free trial.
2. Methods
After local ethics committee approval and patient consent,
men over 70 years, age in an outpatient clinical setting
presenting prostatic obstruction with AUR and who after
one week of full dose alpha-blocker and 5-alpha-reductase
inhibitor have failed a catheter-free trial were invited to be
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enrolled in a prospective, uncontrolled study to establish the
rate of catheter dependence and its predictors in elderly men
after diethylstilbestrol (DES) 1mg plus aspirin 100mg over 4
weeks. Catheter-free trial was defined as resolution of AUR
after bladder decompression by catheterization.
All patients underwent urinalysis, ultrasonography
accessing prostate volume, bladder and upper urinary
tract and laboratorial work up including serum creatinine.
Drained urine volumes were recorded at the first catheter-
ization. The primary end point was the number of catheter-
free versus catheter dependent patients.
Exclusion criteria were cardiovascular morbidity, com-
promised renal function measured by abnormal creatinine
levels, hematuria, bladder stone, upper urinary tract dila-
tion, urinary tract infection, neurological diagnosis, DES or
aspirin intolerance/contraindication, and prostate cancer
diagnosis or suspicion.
Multivariate analysis was utilized to identify independent
predictors of TWOC and the level of significance was 𝑃 <
0.05.
3. Results
Among 69 patients screened, 16 were excluded due to car-
diovascular morbidity (𝑛 = 7), upper urinary tract dilation
(𝑛 = 3), compromised renal function (𝑛 = 2), urinary tract
infection (𝑛 = 2) and neurological diagnosis (𝑛 = 2).
The proposed protocol was offered to 53 consecutive
patients, 5 preferred immediate channel transurethral resec-
tion of prostate (TURP) and 48 concluded the trial. Two
patients underwent prostate biopsy to rule out prostate cancer
before trial enrollment.
Among the analyzed patients, mean age was 76.6 years
(70–84), mean prostate volume 90 cm3 (42–128), and mean
follow-up 204 days; 58% (28/48) were passing urine and 42%
(20/48) were catheter dependent after 4 weeks DES trial.
Mean age and initial retention drained urine volume
of catheter dependent patients were 82.4 years and 850mL
compared with 74.6 years and 530mL in catheter-free men,
respectively. Age and drained urine volume were indepen-
dent predictors of TWOC (both 𝑃 < 0.01). Seventy-five
percent (6/8) of patients 80 years and older were catheter
dependent.
Transient nipple/breast tenderness and gynecomastia
were the only adverse effects reported by 21% (10/48) and
4% (2/48), respectively. No patient presented severe compli-
cations.
4. Discussion
Considering the morbidity of long-term catheter and the fact
that some patients refuse surgical treatment, advancement of
prostatic obstruction medical treatment is merited.
Offering TURP to a patient must be placed in the context
of their anesthetic risk, wishes, and alternative strategies. At
the same time, prolonged use of indwelling catheter (IDC)
is accompanied by several side effects and complications
[10]. In addition, the cost implication of having an IDC is
considerable [11].
In this context, clean intermittent self-catheterization
(CISC) adds the convenience of not having an external device
and the maintenance of sexual activity. About half of the
patients using CISC will eventually void spontaneously and
the incidence of urinary tract infection is half of thatwith IDC
even after TURP. However, CISC requires a dedicated staff
to efficiently teach the method, and patients able to manage
CISC tend to be younger and have smaller prostates [12].
Previous proof of concept and safety of hormonal treat-
ment for prostatic obstruction was presented for patients
with prostate cancer and AUR [13, 14] and also short-term
hormonal treatment for prostatic obstruction in a noncancer
scenario [15, 16].
Considering the increasingly aging population and that
less surgical morbidity, longer life expectancy, and higher
impact of hormonal treatment in terms of quality of life and
collateral effects are expected among youngers, the elderly
were selected to this preliminary protocol.
Aiming acceptable adverse effects and risk-benefit bal-
ance, hormones were discontinued after 4 weeks and also
antiplatelet was added to treatment. Besides, the local ethics
committee encouraged this preliminary trial before advanc-
ing. Additionally, 5 alpha reductase inhibitor plus alpha
blocker were continued indefinitely supposedly to limit the
likely decrease in the initial success rate with time.
Based on the safety and relatively low morbidity of the
current study, longer trials of hormones are warranted and
would add to this modest 58%medium term success rate. On
the other hand, if confirmed in larger trials with longer follow
up, it is promising the fact that more than half the patients
were initially rescued after having failed a TWOC.
Moreover, considering surgical hemorrhagic complica-
tions, medical hormonal treatment may be a potential
(definitive or palliative) alternative to patients under oral
anticoagulation once it precludes cardiovascular morbidity
and at the same time increases surgical morbidity.
In case of incomplete response, the proposed alternative
not only refers to how to avoid any surgical treatment, but
also allows how to achieve a better condition for a future
surgical procedure in a catheter-free patient, avoiding bladder
bacterial colonization and its potential consequences once
surgerymorbidity for catheterized patients is potentially risky
compared to those catheter free when treated [10].
Varenhorst and Alund have described 65.6% (80/122)
catheter-free rate six months after starting endocrine therapy
in prostate cancer patients under AUR. The mean period of
catheterization for the 80 patients who responded was 2.7
months after orchiectomy and 3.4 months during estrogen
treatment [13].
Also, in prostate cancer patients not candidates for
curative treatment, androgen deprivation therapy improved
lower urinary tract symptoms, objective voiding parameters,
and prostate volume in a clinically relevantmannerwithin the
firstmonth [14], supporting the effect of short-term treatment
observed in the present study.
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Even examining patients without cancer diagnosis,
Narayan et al. described that flutamide reduced the prostate
volume in a dose-related fashion and resulted in an increase
in peak flow rate at 4 weeks (250mg three times daily, 𝑃 value
< 0.05) [15] and Onu showed the effects of depot medrox-
yprogesterone 150mg single-dose intramuscular injection in
a similar fashion, as a safe and effective treatment for prostatic
obstruction where potency is a secondary consideration [16].
Advanced age and higher drained urine volume as predic-
tors of treatment failure in the present study denote chronic
retention with poor detrusor function (elderly bladder) that
represents risk factors of both surgical and conservative
therapy failure [17, 18] and that should be confirmed in future
studies. However, although the present study failed to include
bladder functional evaluation, it would add important mor-
bidity given the substantial invasiveness of urodynamic study,
mainly in the elderly.
Furthermore, patients reported good tolerance, which
could be related with elderly “natural” hormonal decline,
where sexual function is a secondary consideration. Future
studies should consider erectile function and testosterone
level dosages before and after treatment.
Although to the best of our knowledge, this is the first
report of DES to rescue a selected elderly population present-
ing with AUR who failed a catheter-free trial, it is important
to highlight that this is a preliminary study with limitations
such as no data regarding detrusor function (urodynamic
study) or contributors to impaired detrusor function (fecal
impaction and medications), relatively small number of
patients included, no distinction between spontaneous and
precipitated AUR, relatively short follow-up, the lack of con-
trol arm (i.e., a second trial without catheter after continuous
full dose alpha-blocker and 5-alpha-reductase inhibitor over
4 weeks), no data regarding PSA, and testosterone and
prostate volume variations during the study.
Finally, although 32% of the patients with successful
TWOC will require surgery within 8 to 24 months of follow-
up [19], the good results reported might be related to the
exclusion criteria that may input selection bias for those with
better bladder function, reducing the generalizability of the
data.
5. Conclusion
Low dose diethylstilbestrol associated with aspirin seems
to be a safe and effective minimally invasive alternative to
rescue a significant portion of a selected elderly population
presenting with AUR secondary to prostatic obstruction who
failed a catheter-free trial after one week of full dose alpha-
blocker and 5-alpha-reductase inhibitor and refuses immedi-
ate channel TURP.
Higher drained urine volume and advanced age were
associated with higher failure. Overall, patients reported
good tolerance. Larger trials with longer follow-up are war-
ranted before systematic utilization of hormonal therapy is
anticipated in this scenario.
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